Cliff Megerian, MD
- President, University Hospitals, University Hospitals
- Professor, CWRU School of Medicine
- Chair, Auditory Surgery and Hearing Sciences, UH Cleveland Medical Center
- Acoustic Neuromas
- Chronic Ear Disease
- Cochlear Implantation
- Ear, Nose and Throat
- Head and Neck Cancer
- Hearing Loss
- Meniere's Disease
- Skull Base Surgery
- Surgery for Hearing Loss and Tumor
Patient Satisfaction Reviews
4.9 out of 5
Patient Comments (7)
Reviewed On 1/18/2020
Megarian is the BEST!
Reviewed On 12/1/2019
Best ENT - extremely knowledgeable but can speak at a non-medical level to make the patient fully understand the nature of their condition. I would highly recommend this doctor.
Reviewed On 11/8/2019
During this post-op follow-up appointment,Dr. Cliff Megerian patiently explained in very understandable language what had been accomplished during the cranial surgery. He then addressed my every concern and answeredmy every question.
Reviewed On 10/26/2019
Dr Mergerian is a great Doctor, and I trust my complete hearing to him. Thanks Dr. M
Reviewed On 10/25/2019
Dr. Mergerian is always very attentive and listens to me. The affliction I have has been difficult to diagnose and treat.Dr. Magerian's nurse is very helpful during my visits and afterwards making appointments and prescriptions.
Reviewed On 8/31/2019
very good experience
Reviewed On 7/26/2019
I'm pleased.with Dr. Mergerian and the trearptment he gave me.
- Neurotology - American Board of Otolaryngology - Head and Neck Surgery
- Otolaryngology - Head and Neck Surgery - American Board of Otolaryngology - Head and Neck Surgery
Fellowship | Otology and Neurotology
Otology and Neurotology - Massachusetts Eye And Ear Infirmary (1993 - 1995)
Residency | Otolaryngology
Otolaryngology - University Hospitals Of Cleveland (1989 - 1993)
Internship | General Surgery
General Surgery - University Hospitals Of Cleveland (1988 - 1989)
University Of Michigan Medical School (1988)
Michigan State University (1984)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Cliff Megerian did not disclose any Outside Relationships with Industry.